The European Commission (EC) has approved Xofluza (baloxavir marboxil) in children aged one year and older.
Developed by Swiss pharma giant Swiss pharma giant Roche (ROG: SIX), Xofluza is intended for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza. Post-exposure prophylaxis aims to prevent flu in individuals following contact with someone infected with the influenza virus. The approval comes at a time when fears of a ‘twindemic’ have been realised as Covid and flu cases rise.
The Commission’s decision is based on the results of the Phase III miniSTONE-2 and BLOCKSTONE studies. This approval marks the first single-dose, oral influenza medicine approved in Europe for children, and now means that Xofluza can be used to treat and prevent uncomplicated influenza in children aged one year and above, and in adolescents and adults.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze